GLAND

Gland Pharma Financial Results

₹3,156.20+4.99%
Market cap
₹52,000 crore
P/E
46.1
P/B
5.02
ROE
10.5%
Dividend yield
0.63%

For the year ended Mar 2021, Gland Pharma reported revenue of ₹3,463 crore and net profit of ₹997 crore, against ₹4,401 crore and ₹1,212 crore a year earlier.

Gland Pharma annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Gland Pharma annual profit and loss (₹ crore)
ItemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue3,4634,4013,5925,6425,5846,4036,698
Expenses2,1612,8912,5754,3014,3164,7734,946
Operating profit1,3021,5101,0171,3411,2681,6301,752
Operating margin %38%34%28%24%23%25%26%
Other income135224191158210288291
Interest35622373022
Depreciation99110147345378424434
Profit before tax1,3351,6191,0551,1331,0631,4651,587
Tax %25%25%26%32%34%30%29%
Net profit9971,2127817726991,0271,129
EPS (₹)60.5373.5747.4246.9042.4062.3568.51
Dividend payout %———————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Gland Pharma financial results — frequently asked questions

What is Gland Pharma's annual revenue and net profit?

For the financial year ended Mar 2021, Gland Pharma's revenue was ₹3,463 crore and net profit ₹997 crore; net profit fell 17.74% from ₹1,212 crore in Mar 2022.

How fast has Gland Pharma grown over three years?

From Mar 2024 to Mar 2021, Gland Pharma's revenue grew at a compound annual rate of -15.0% and net profit at 8.9%. Past growth does not indicate future results.

What is the EPS of Gland Pharma?

Annual EPS for Mar 2021 was ₹60.53.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Gland Pharma With ATS

Track GLAND live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.